SIGA Technologies Toekomstige groei

Future criteriumcontroles 0/6

SIGA Technologies zal naar verwachting zijn omzet verhogen met 7.5% per jaar.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.7%
Inkomstengroei	7.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket

Nov 21

Investors Shouldn't Be Too Comfortable With SIGA Technologies' (NASDAQ:SIGA) Earnings

Nov 15

SIGA Technologies, Inc. (NASDAQ:SIGA) Not Doing Enough For Some Investors As Its Shares Slump 34%

Sep 14

SIGA Technologies: Shares Tanking On Mpox Study Miss, Turbulence May Be Temporary

Aug 15

SIGA Technologies, Inc. (NASDAQ:SIGA) Held Back By Insufficient Growth Even After Shares Climb 31%

Jul 14

SIGA Technologies: BARDA Contract Renewal Required To Sustain Recent Momentum (Rating Downgrade)

Jun 13

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company

Mar 31

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Mar 25

Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

Mar 19

SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg

Aug 17

Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

Aug 12

SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise

Aug 09

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

Aug 01

SIGA Technologies: Buy Monkeypox

Jul 25

Siga Technologies receives approval from UK for tecovirimat

Jul 08

SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak

May 27

SIGA Technologies: There's An Assured Market For A Smallpox Vaccine

Dec 12

It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year

Jun 08

SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX

Apr 28

Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years

Feb 22

Winst- en omzetgroeiprognoses

NasdaqGM:SIGA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	184	N/A	N/A	N/A	1
12/31/2024	160	N/A	N/A	N/A	1
9/30/2024	174	86	71	71	N/A
6/30/2024	173	84	74	74	N/A
3/31/2024	157	79	64	64	N/A
12/31/2023	140	68	95	95	N/A
9/30/2023	35	-5	8	8	N/A
6/30/2023	98	28	8	8	N/A
3/31/2023	109	33	9	9	N/A
12/31/2022	111	34	42	42	N/A
9/30/2022	215	108	66	66	N/A
6/30/2022	147	72	72	72	N/A
3/31/2022	139	70	73	73	N/A
12/31/2021	134	69	11	11	N/A
9/30/2021	56	16	41	41	N/A
6/30/2021	95	44	71	71	N/A
3/31/2021	127	64	63	63	N/A
12/31/2020	125	56	72	72	N/A
9/30/2020	91	32	11	11	N/A
6/30/2020	55	6	-20	-20	N/A
3/31/2020	19	-18	-15	-15	N/A
12/31/2019	27	-7	-18	-18	N/A
9/30/2019	24	50	-8	-8	N/A
6/30/2019	487	439	78	78	N/A
3/31/2019	486	435	77	77	N/A
12/31/2018	477	422	69	69	N/A
9/30/2018	477	359	64	64	N/A
6/30/2018	7	-39	N/A	-30	N/A
3/31/2018	9	-39	N/A	-26	N/A
12/31/2017	12	-36	N/A	-18	N/A
9/30/2017	18	-36	N/A	-35	N/A
6/30/2017	21	-36	N/A	-84	N/A
3/31/2017	19	-38	N/A	-108	N/A
12/31/2016	15	-40	N/A	-117	N/A
9/30/2016	12	-49	N/A	-107	N/A
6/30/2016	9	-46	N/A	-37	N/A
3/31/2016	8	-43	N/A	9	N/A
12/31/2015	8	-39	N/A	11	N/A
9/30/2015	5	-38	N/A	23	N/A
6/30/2015	5	-273	N/A	20	N/A
3/31/2015	4	-269	N/A	-9	N/A
12/31/2014	3	-265	N/A	14	N/A
9/30/2014	3	-251	N/A	4	N/A
6/30/2014	4	-16	N/A	74	N/A
3/31/2014	5	-16	N/A	83	N/A
12/31/2013	6	-17	N/A	58	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van SIGA boven de spaarquote ( 2.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van SIGA naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van SIGA naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: De omzet van SIGA ( 7.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van SIGA ( 7.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SIGA naar verwachting over 3 jaar hoog zal zijn

SIGA Technologies Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket

Investors Shouldn't Be Too Comfortable With SIGA Technologies' (NASDAQ:SIGA) Earnings

SIGA Technologies, Inc. to Report Q3, 2024 Results on Nov 07, 2024

SIGA Technologies, Inc. (NASDAQ:SIGA) Not Doing Enough For Some Investors As Its Shares Slump 34%

SIGA Technologies: Shares Tanking On Mpox Study Miss, Turbulence May Be Temporary

SIGA Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024

SIGA Technologies, Inc. (NASDAQ:SIGA) Held Back By Insufficient Growth Even After Shares Climb 31%

SIGA Technologies: BARDA Contract Renewal Required To Sustain Recent Momentum (Rating Downgrade)

First quarter 2024 earnings released: EPS: US$0.14 (vs US$0.013 loss in 1Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

SIGA Technologies, Inc. to Report Q1, 2024 Results on May 07, 2024

SIGA Technologies, Inc., Annual General Meeting, Jun 11, 2024

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 17%

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

Investor sentiment improves as stock rises 63%

Upcoming dividend of US$0.60 per share

Full year 2023 earnings: EPS and revenues miss analyst expectations

Siga Technologies, Inc. Declares A Special Cash Dividend, Payable on April 11, 2024

SIGA Technologies, Inc. to Report Q4, 2023 Results on Mar 12, 2024

The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)

High number of new directors

New major risk - Revenue and earnings growth

Siga Technologies, Inc. Appoints Diem Nguyen to the Board of Directors

Third quarter 2023 earnings released: US$0.006 loss per share (vs US$0.45 profit in 3Q 2022)

SIGA Technologies, Inc. to Report Q3, 2023 Results on Nov 07, 2023

SIGA Technologies, Inc. Appoints Jay K. Varma as EVP and Chief Medical Officer

Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.028 profit in 2Q 2022)

SIGA Technologies, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Inaugural dividend of US$0.45 per share

First quarter 2023 earnings released: US$0.013 loss per share (vs US$0.005 loss in 1Q 2022)

SIGA Technologies, Inc. Declares a Special Cash Dividend, Payable on June 1, 2023

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023

Investor sentiment improved over the past week

Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?

High number of new directors

SIGA Technologies, Inc. Announces Directorate Appointments

Third quarter 2022 earnings released: EPS: US$0.45 (vs US$0.042 loss in 3Q 2021)

SIGA Technologies, Inc. to Report Q3, 2022 Results on Nov 03, 2022

SIGA Technologies, Inc. Provides Update on Progress in Clinical Trials to Assess Use of Tpoxx ® (Tecovirimat) for Treatment of Monkeypox

SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX

Investor sentiment deteriorated over the past week

Siga monkeypox therapy undergoes NIH-led late-stage trial

Investor sentiment deteriorated over the past week

Scientists behind key COVID study run monkeypox trial for SIGA therapy

Now 21% undervalued

SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg

Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise

James Antal Provides Notice to SIGA Technologies, Inc. of His Resignation from the Board of Directors

Second quarter 2022 earnings released: EPS: US$0.028 (vs US$0.002 in 2Q 2021)

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

SIGA Technologies, Inc. to Report Q2, 2022 Results on Aug 04, 2022

SIGA Technologies: Buy Monkeypox

Investor sentiment improved over the past week

SIGA Technologies Receives Approval from UK for Tecovirimat

Siga Technologies receives approval from UK for tecovirimat

SIGA Technologies, Inc.(NasdaqGM:SIGA) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Independent Director exercised options and sold US$70k worth of stock

Investor sentiment improved over the past week

SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations

SIGA Technologies, Inc. Declares a Special Dividend of the Company, Payable on June 2, 2022

High number of new directors

SIGA Technologies, Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

SIGA Technologies, Inc. Announces Start of Tpoxx® Post-Exposure Prophylactic Clinical Trials